In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PureTech’s Problem-Solving Skills Target The BIG Picture

Interim Chair Viehbacher Guides Unique Strategy

Executive Summary

PureTech Health has amassed niche expertise and built a unique structure that allows it to develop technologies for unmet needs, in the separate but related areas of brain-immune-gut. And now, with the experienced ex-Sanofi CEO Chris Viehbacher as interim chair, PureTech can target a smooth path to its next growth stages in the “BIG Axis.” Senior executives Eric Elenko and Joep Muijrers reveal more about the focus and aims of the Boston, US group.

You may also be interested in...



Device Week, 7 August 2020: Brexit, COVID-19 & NHS Reform Augur Big 12 Months For UK Medtech

In this Device Week, Ashley Yeo asks PB Consulting managing director Dan Jones about the adjustments needed by UK medtechs as they face a confluence of change brought about by Brexit, COVID-19 and NHS reform, at a time when the MHRA is also coming under increased scrutiny. 

Carlo Rivis: Know Your Own Value In Bringing Disruptive Innovation To Market

Entrepreneur Carlo Rivis, one of In Vivo’s Rising Leaders, brought his disruptive innovation approaches to in-silico trials and digital avatar developer Computational Life, and now he is doing the same at Innovation Discovery.

Medtechs’ View Of UK Brexit Deal: More Certainty, But Still No Detail

COVID-19 is of no lesser importance to the UK medtech industry, but attention is now refocusing on Brexit, future regulation and trade deals.

Topics

Related Companies

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel